Company
Aegle Therapeutics
Aegle Therapeutics is a pioneer in regenerative medicine developing extracellular vesicle (EV) therapy to meaningfully improve the lives of those suffering from debilitating rare diseases, including dystrophic epidermolysis bullosa (DEB) and other severe dermatological disorders.
Also known as Aegle Therapeutics Corp
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 19 October 2026
About
We are a clinical-stage developer of novel, cell-free therapies using EVs to deliver a natural biomolecular payload to treat disorders with significant unmet medical need.
Funding snapshot
- Total raised
- $19.7MSum of rounds, as of 2026-10-19Source (opens in a new tab)
- Latest round
- Undisclosed, $2.3M2026-08-04
Funding rounds
- Round, 2026
- $2.3M2026-08-04, SEC form D sold
- Round, 2025
- $456K2025-12-30, SEC form D sold, 10 investors
- Grant
- 2020-10-08
- Series A
- $6.5M2020-09-29, Company stated
- Round, 2020
- $4M2020-01-07, Company stated
- Round, 2020
- $6.5M2020-01-03, SEC form D sold, 8 investors
Products
- Other
- AGLE-102
Loading relationship preview